880 reports of this reaction
3.1% of all OBINUTUZUMAB reports
#6 most reported adverse reaction
THROMBOCYTOPENIA is the #6 most commonly reported adverse reaction for OBINUTUZUMAB, manufactured by Genentech, Inc.. There are 880 FDA adverse event reports linking OBINUTUZUMAB to THROMBOCYTOPENIA. This represents approximately 3.1% of all 28,651 adverse event reports for this drug.
Patients taking OBINUTUZUMAB who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is moderately reported among OBINUTUZUMAB users, representing a notable but not dominant share of adverse events.
In addition to thrombocytopenia, the following adverse reactions have been reported for OBINUTUZUMAB:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 880 FDA reports for OBINUTUZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 3.1% of all adverse event reports for OBINUTUZUMAB, making it a notable side effect.
If you experience thrombocytopenia while taking OBINUTUZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.